Company News

August 14, 2024

Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005

— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Frederick, MD, Aug. 14, 2024 … Read More

February 2, 2017

Meet Our Clients: Jeff Strovel, CEO of VERALOX Therapeutics

Thrombocytopenia is a big word that can carry big consequences for those struggling with rare blood disorders, especially among those using heparin to treat and prevent blood clots. And for … Read More